Literature DB >> 19841558

Malignant melanoma: a retrospective series from a regional cancer center in India.

Kuldeep Sharma1, Bidhu K Mohanti, Gaura K Rath.   

Abstract

PURPOSE: To present our experience in treating malignant melanoma patients. METHODS AND MATERIALS: All melanoma patients treated at the Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi, India, from 1995 to 2007 were studied retrospectively. The endpoints were loco-regional recurrence, distant recurrence, recurrence-free survival (RFS), and duration of follow-up (DOFU). RFS and DOFU were analyzed with respect to the factors like age, sex, tissue of origin, site of disease, number of nodes, lymphadenopathy, ulceration, stage, and operability to find out any association.
RESULTS: Seventy-two patients were found evaluable with 40 males and 32 females (median age 46.5 years). Eye was the commonest primary site with visual disturbance as the commonest symptom. Overall, 87% of the lesions were single, with most of the nonocular lesions presenting in the advanced stage. During the disease course, regional lymphadenopathy and distant metastases were seen in 33% and 32% of cases, respectively. Highest incidence of lymphadenopathy was seen in skin lesions and in primaries from trunk and extremities. Of all treated patients, 47% achieved complete response, 18% partial response, and others had either stable or progressive disease. The median DOFU was 6.2 months. RFS was studied only in curatively treated cases with a median of 10 months. Operability at presentation was the only prognostic factor influencing DOFU.
CONCLUSION: Malignant melanoma is an uncommon disease in India carrying a lot of morbidity due to late presentation. Its management is still not clear regarding the optimum use and schedule of treatment modalities. More prospective studies in the future are required to come to a definite conclusion.

Entities:  

Mesh:

Year:  2009        PMID: 19841558     DOI: 10.4103/0973-1482.57122

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  7 in total

1.  Pigmented Pre-malignant and Malignant Lesions of Skin with Special Reference to Atypical Presentations.

Authors:  Nadia Shirazi; Rashmi Jindal; Sneha Singh; Meena Harsh; Sohaib Ahmad
Journal:  J Clin Diagn Res       Date:  2015-07-01

2.  A retrospective study of malignant melanoma from a tertiary care centre in Saudi Arabia from 2004 to 2016.

Authors:  A Alshedoukhy; P Cahusac; J Kashir; F H Alkhawaja; A M M Tulbah; K Anwar
Journal:  Clin Transl Oncol       Date:  2019-06-29       Impact factor: 3.340

3.  Cytodiagnosis of epithelioid malignant melanoma (amelanotic) and diagnostic dilemmas.

Authors:  Santosh Kumar Mondal; Palash Kumar Mondal; Sujit Kumar Dutta
Journal:  J Cytol       Date:  2014 Oct-Dec       Impact factor: 1.000

4.  Early Experience with Dabrafenib-Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma-A Single-Center Experience.

Authors:  Sandip Ganguly; Joydeep Ghosh; Deepak Mishra; Gautam Biswas; Deepak Dabkara; Somanth Roy; Bivas Biswas
Journal:  South Asian J Cancer       Date:  2021-11-24

5.  Not so 'rare'-an example of malignant melanoma in India: report from a tertiary cancer centre.

Authors:  Bivas Biswas; Gautam Biswas; Sandip Ganguly; Joydeep Ghosh; Somnath Roy; Manas Kumar Roy; Amrit Pipara; Jagriti Karmakar; Navonil Mukherjee; Santam Chakraborty; Deepak Kumar Mishra; Divya Midha; Deepak Dabkara
Journal:  Ecancermedicalscience       Date:  2021-12-16

6.  Knowledge and Attitude of General Population toward Effects of Sun Exposure and Use of Sunscreens.

Authors:  Shweta Bharat Agarwal; Kiran Godse; Sharmila Patil; Nitin Nadkarni
Journal:  Indian J Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.494

7.  Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis.

Authors:  Peter Shaw; Greg Raymond; Katherine S Tzou; Siddhartha Baxi; Ravishankar Ram Mani; Suresh Kumar Govind; Harish C Chandramoorthy; Palanisamy Sivanandy; Mogana Rajagopal; Suja Samiappan; Sunil Krishnan; Rama Jayaraj
Journal:  Genes (Basel)       Date:  2022-01-08       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.